Difference between revisions of "Part:BBa K4165143"
Line 7: Line 7:
 
===Usage and Biology===
 
===Usage and Biology===
 
KNT is a peptide tested as an inhibitor for tau aggregation. Its half maximal concentration for tau fibril formation inhibition is 182.8 μM, it can bind to tau at PHF seed (VQIVYK), its amino acid sequence is KNTPQHRKLRLS. It can penetrate cell membrane and cytosol of N2a cells
 
KNT is a peptide tested as an inhibitor for tau aggregation. Its half maximal concentration for tau fibril formation inhibition is 182.8 μM, it can bind to tau at PHF seed (VQIVYK), its amino acid sequence is KNTPQHRKLRLS. It can penetrate cell membrane and cytosol of N2a cells
 +
 +
 
<!-- -->
 
<!-- -->
−
<span class='h3bb'>Sequence and Features</span>
+
<span class='h3bb'> <p style=" font-weight: bold; font-size:17px;"> Sequence and Features</p> </span>
 
<partinfo>BBa_K4165143 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K4165143 SequenceAndFeatures</partinfo>
  

Revision as of 13:33, 6 October 2022


KNT Peptide

Tau binding peptide targeting the PHF seed of Tau

Usage and Biology

KNT is a peptide tested as an inhibitor for tau aggregation. Its half maximal concentration for tau fibril formation inhibition is 182.8 μM, it can bind to tau at PHF seed (VQIVYK), its amino acid sequence is KNTPQHRKLRLS. It can penetrate cell membrane and cytosol of N2a cells


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

Reference

1. Dammers, C., Yolcu, D., Kukuk, L., Willbold, D., Pickhardt, M., Mandelkow, E., ... & Funke, S. A. (2016). Selection and Characterization of Tau Binding ᴅ-Enantiomeric Peptides with Potential for Therapy of Alzheimer Disease. PLoS One, 11(12), e0167432.